BPG is committed to discovery and dissemination of knowledge
Articles in Press
3/21/2025 11:01:03 AM | Browse: 64 | Download: 0
Category |
Cell & Tissue Engineering |
Manuscript Type |
Basic Study |
Article Title |
RNA interference-mediated osteoprotegerin silencing increases the receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio and promotes osteoclastogenesis
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Song-Guan Wei, Hui-Hong Chen, Liu-Rong Xie, Yuan Qin, Yu-Ying Mai, Lin-Hui Huang and Hong-Bing Liao |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Natural Science Foundation of China |
82160192 |
Guangxi Science and Technology Program |
2023AB23037 |
|
Corresponding Author |
Hong-Bing Liao, Guangxi Key Laboratory of Oral and Maxillofacial Rehabilitation and Reconstruction, College & Hospital of Stomatology, Guangxi Medical University, No. 22 Shuangyong Road, Qingxiu District, Nanning 530021, Guangxi Zhuang Autonomous Region, China. hongbing_liao@gxmu.edu.cn |
Key Words |
Osteoprotegerin; Receptor activator of nuclear factor-kappa B ligand; Bone marrow-derived mesenchymal stem cells; RNA interference; Osteoclast; Bone scaffold |
Core Tip |
This study reports, for the first time, that enhancing the receptor activator of nuclear factor-kappa B ligand/osteoprotegerin (RANKL/OPG) ratio through RNA interference promotes osteoclastogenesis. Our findings reveal a significant upregulation of RANKL mRNA levels after OPG gene silencing. The study demonstrates a significant downregulation of OPG mRNA and protein levels. The increase in the RANKL/OPG ratio significantly promotes osteoclastogenesis. This study provides a new theoretical basis and molecular targets for degrading bone scaffolds and bone tissue repair. |
Citation |
<p>Wei SG, Chen HH, Xie LR, Qin Y, Mai YY, Huang LH, Liao HB. RNA interference-mediated osteoprotegerin silencing increases the receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio and promotes osteoclastogenesis. <i>World J Stem Cells</i> 2025; 17(4): 101290</p> |
 |
Received |
|
2024-09-10 03:29 |
 |
Peer-Review Started |
|
2024-09-10 03:29 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2024-10-28 08:16 |
 |
Revised |
|
2024-12-13 09:22 |
 |
Second Decision |
|
2025-02-18 02:43 |
 |
Accepted by Journal Editor-in-Chief |
|
2025-02-19 01:15 |
 |
Accepted by Executive Editor-in-Chief |
|
2025-03-21 11:01 |
 |
Articles in Press |
|
2025-03-21 11:01 |
 |
Publication Fee Transferred |
|
2024-12-23 03:47 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-04-10 03:33 |
ISSN |
1948-0210 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345